A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Donna R. Cryer et al.|Hepatology|2023Cited by 2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Journal of Hepatology|2023Cited by 2.7k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Annals of Hepatology|2023Cited by 789
Endpoints and clinical trial design for nonalcoholic steatohepatitisArun J. Sanyal, Arthur J. McCullough, Elizabeth M. Brunt et al.|Hepatology|2011Cited by 757